Sunday, April 5, 2020 • 2:00 PM - 5:00 PM
SDCC, Room 2
Sponsored by the ASIP Liver Pathobiology Scientific Interest Group
Chair: Kari Nejak-Bowen, MBA, PhD • University of Pittsburgh
Session Description: In this session, we will approach the problem of non-alcoholic fatty liver disease (NAFLD) through improved understanding of the cellular and molecular mechanisms involved in disease progression. Recent advances in gut-liver axis, microbiome, and inflammation in the pathogenesis of NAFLD will be also discussed. Finally, we will explore novel signaling pathways that can be targeted for treatment of NAFLD.
- Chair - Welcome and Introductions
- 2:00 PM - 2:30 PM
Cholesterol and Bile Acid Metabolism in Fatty Liver Disease
Tiangang Li, PhD • University of Kansas Medical Center
- 2:30 PM - 3:00 PM
Bile Acid Receptors and NAFLD
Huiping Zhou, PhD • Virginia Commonwealth University
- 3:00 PM - 3:30 PM
Gut Permeability in NASH: Role of Mucosal Immune Cells, Microbiota and Bile Acids
Reben Raeman, MS, PhD • University of Pittsburgh
- 3:30 PM - 4:00 PM
Microbiome and Alcoholic Liver Disease
Bernd Schnabl, MD • University of California San Diego
- 4:00 PM - 4:30 PM
Inhibition of EGFR Receptor Prevents and Reverses Extreme NAFLD
George K. Michalopoulos, MD, PhD • University of Pittsburgh
- 4:30 PM - 5:00 PM
Genetics and NASH
Rohit Loomba, MD, MHSc • University of California, San Diego
- Questions and Answers
